Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue SUPPL. 1, 1998, Pages

  Leysen, Josée E ^a   Janssen, Paul M F ^a   Heylen, Lieve ^a   Gommeren, Walter ^a   Van Compel, Paul ^a   Lesage, Anne S ^a   Megens, Anton A H P ^a   Schotte, Alain ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BROMOCRIPTINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ECOPIPAM; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PALIPERIDONE; PIPAMPERONE; QUETIAPINE; QUINPIROLE; RISPERIDONE; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SERTINDOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

COGNITIVE DEFECT; CONFUSION; DELIRIUM; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TARDIVE DYSKINESIA;

EID: 0031972209     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Davis KL, Kahn RS, Ko G et al (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-86.
2. Leysen JE, Niemegeers CJE, Tollenaere JP et al (1978) Serotonergic component of neuroleptic receptors. Nature 272: 168-71.
3. Toru M, Kurumaji A, Ishimaru M (1994) Excitatory amino acids: implications for psychiatric disorders research. Life Sci 55: 1683-99.
4. Delay J, Deniker P, Harl JM et al (1952) Traitements d'états confusionnels par le chlorhydrate de diéthylaminopropyl-N-chlorophénothiazine (4560 RP). Ann Med Psychol 110: 398-403.
5. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140-4.
6. Van Rossum JM (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160: 492-4.
7. Randrup A, Munkvad I (1972) Influence of amphetamines on animal behaviour: stereotypy, functional impairment and possible animal-human correlations. Psychiatr Neurol Neurochir 75:193-202.
8. Seeman P (1995) Dopamine receptors and psychosis. Sci Am 273: 28-37.
9. Baldessarini RJ, Tarazi FI (1996) Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Rev Psychiatry 3: 301-25.
10. 1-like agonists in rats. J Neurosci 16: 4823-34.
11. Goldman-Rakic PS (1995) Psychopathology and neuropathology of prefrontal cortex in schizophrenia. In: Alfred Benzon symposium 38: Schizophrenia, an integrated view (ed R Fog, J Gerlach, R Hemmingsen) 126-36. Munksgaard, Copenhagen.
12. 1 receptors in prefrontal cortex. Nature 376: 572-5.
13. 1 receptor antagonists in rodents, in primates and in humans. In: Alfred Benzon symposium 38: Schizophrenia, an integrated view (ed R Fog, J Gerlach, R Hemmingsen) 300-9. Munksgaard, Copenhagen.
14. 2 receptor occupancy studies and clinical response. Br J Psychiatry 168 (suppl. 29): 40-4.
15. 2-dopamine receptors in schizophrenia. In: Alfred Benzon symposium 38: Schizophrenia, an integrated view (ed R Fog, J Gerlach, R Hemmingsen) 190-9. Munksgaard, Copenhagen.
16. 125I]2′-iodospiperone. Psychopharmacol 110: 27-36.
17. Schotte A, Janssen PFM, Gommeren W et al (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol 124: 57-73.
18. 2 receptors. Psychopharmacol 112: S40-S54.
19. Lahti AC, Albert PK, Warfel DT et al (1995) Novel antidopaminergic strategies for the treatment of schizophrenia. Schizophr Res 15: 157.
20. 4 receptors in the action and development of antipyschotic agents. Drags 51: 7-11.
21. 4 receptor. Mol Pharmacol 50: 1658-64.
22. 4 receptors in GABAergic neurons of the primate brain. Nature 381: 245-8.
23. 4 receptors elevated in schizophrenia. Nature 365: 441-5.
24. 4 receptor antagonist. Trends Pharmacol Sci 18: 186-8.
25. Tedeschi DH, Tedeschi RE, Fellows EJ (1961) Central serotonin antagonist activity of a number of phenothiazines. Arch Int Phamacodyn Ther 132: 172-9.
26. Deberdt R (1976) Pipamperone (Dipiperon®) in the treatment of behaviour disorders. A large-scale multicentre evaluation. Acta Psychiatr Belg 76: 157-66.
27. Ansoms C, De Backer-Dierick G, Vereecken JLTM (1977) Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon®). Acta Psychiatr Scand 55: 116-22.
28. 2 antagonist. Mol Pharmacol 27:600-11.
29. 2 receptor blocker. Drug Dev Res 8: 205-11.
30. 2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13: 500-6.
31. 2 antagonistic properties. J Pharmacol Exp Ther 244: 685-93.
32. Leysen JE, Gommeren W, Eens A et al (1988) The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-70.
33. Leysen JE, Janssen PMF, Gommeren W et al (1991) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics, risperidone and ocaperidone. Mol Pharmacol 41: 494-508.
34. Megens AAHP, Awouters FHL, Schotte A et al (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacol 114: 9-23.
35. Davis JM, Janicak PG (1996) Risperidone: a new, novel (and better?) antipsychotic. Psychiatr Ann 26: 78-87.
36. Gallhofer B, Bauer U, Lis S et al (1996) Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6: S2-13-S2-20.
37. Hoyer D, Clarke DE, Fozard JR et al (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46: 157-203.
38. Hoyer D, Martin GR (1996) Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav Brain Res 73: 263-8.
39. Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43: 587-604.
40. Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346: 231-49.
41. 2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res 524: 139-43.
42. 6 with neuropeptides in rat striatum. J Comp Neurol 370: 405-14.
43. 2 receptors in the rat brain. Neurosci 54: 701-17.
44. 2 receptor immunoreactivity on cholinergic neurons of the pontomescencephalic tegmentum shown by double immunofluorescence. Brain Res 627: 49-54.
45. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266: 684-91.
46. 2C receptors in the stimulus effects of hallucinogenic drugs: antagonist correlation analysis. Psychopharmacol 121: 347-56.
47. 2 receptor antagonists - potential in the treatment of psychiatric disorders. CNS Drugs 7: 388-409.
48. Maj J, Mogilnicka E, Przewlocka B (1975) Antagonistic effects of cyproheptadine on neuroleptic-induced catalepsy. Pharmacol Biochem Behav 3: 25-7.
49. Gellman RL, Aghajanian GK (1994) Serotonin 2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neurosci 58: 515-25.
50. 2Areceptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 17: 173-81.
51. Chiang C, Aston-Jones G (1993) A 5-hydroxytryptamine-2 agonist augments gamma-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neurosci 54: 409-20.
52. 2 antagonism. In: Serofonin, from cell biology to pharmacology and therapeutics (ed PM Vanhoutte, PR Saxena, R Paoletti et al) 263-70. Kluwer, Dordrecht.
53. Svensson TH, Tung CS (1989) Local cooling of prefrontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol Scand 136: 135-6.
54. 2 antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacol 98: 45-50.
55. 1-adrenoreceptor antagonism. J Clin Psychopharmacol 15: 11S-18S.
56. Pehek EA (1996) Local infusion of the serotonin antagonist ritanserin or ICS205 930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse 24: 12-19.
57. Abramowski D, Rigo M, Due D et al (1995) Localization of the 5-hydroxytryptamine 2C receptor protein in human and rat brain using specific antisera. Neuropharmacol 34: 1635-45.
58. 2C serotonin receptors. Nature 374: 542-6.
59. 2A/2C receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacol 126: 24-30.
60. 6 receptor-like material in the rat central nervous system. Brain Res 746: 207-19.
61. 6 receptor in the rat brain: a study using antisense oligonudeotides. J Pharmacol Exp Ther 274: 173-80.
62. 7 receptors in guinea pig brain. Br J Pharmacol 115: 107-16.
63. 7 receptors: molecular biology, functional correlates and possible therapeutic indications. DN & P 10: 214-24.
64. 7 receptor: orphan found. Trends Pharmacol Sci 18: 104-7.
65. 3H] alniditan. Mol Pharmacol 50: 1567-80.